利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.021 秒)

    Method for treating abnormal cell growth
    3.
    发明申请
    Method for treating abnormal cell growth 审中-公开
    治疗异常细胞生长的方法

    公开(公告)号：US20050267140A1

    公开(公告)日：2005-12-01

    申请号：US11140375

    申请日：2005-05-27

    申请人： Langdon Miller ,  Louis Denis ,  Linda Compton

    发明人： Langdon Miller ,  Louis Denis ,  Linda Compton

    IPC分类号： A61K31/407 ,  A61K31/4745 ,  A61K31/513 ,  A61K31/7068

    CPC分类号： A61K31/4745 ,  A61K31/407 ,  A61K31/513 ,  A61K31/7068 ,  A61K2300/00

    摘要： Therapeutic pharmaceutical compositions and methods of treatment of abnormal cell growth comprising a pyrimidine derivative or a pharmaceutically acceptable salt, solvate or prodrug thereof in combination with an oral camptothecin, an oral camptothecin derivative, an indolopyrrocarbazole derivative or a pharmaceutically acceptable salt, solvate or prodrug thereof for the treatment of cancer are described. In one embodiment of the present invention the oral camptothecin derivative is selected from the group consisting of 10-hydroxycamptothecin, 9-aminocamptothecin, 9-nitrocamptothecin, irinotecan, irinotecan salt, SN-38, CPT-11, and topotecan and the indolopyrrocarbazole derivative is edotecarin. In one embodiment the pyrimidine derivative is selected from the group consisting gemcitabine, MTA and capecitabine. In one preferred embodiment, the pyrimidine derivative is capecitabine and the camptothecin derivative is CPT-11.

    摘要翻译： 治疗性药物组合物和治疗异常细胞生长的方法，其包含与口服喜树碱组合的嘧啶衍生物或其药学上可接受的盐，溶剂合物或前药，口服喜树碱衍生物，吲哚并吡咯咔唑衍生物或其药学上可接受的盐，溶剂合物或前药 描述了治疗癌症。 在本发明的一个实施方案中，口服喜树碱衍生物选自10-羟基喜树碱，9-氨基喜树碱，9-硝基喜树碱，伊立替康，伊立替康盐，SN-38，CPT-11和托泊替康，吲哚并吡咯衍生物为 伊曲他宁。 在一个实施方案中，嘧啶衍生物选自吉西他滨，MTA和卡培他滨。 在一个优选的实施方案中，嘧啶衍生物是卡培他滨，喜树碱衍生物是CPT-11。

    METHOD FOR EGFR DIRECTED COMBINATION TREATMENT OF CANCER
    4.
    发明申请
    METHOD FOR EGFR DIRECTED COMBINATION TREATMENT OF CANCER 有权
    方法用于EGFR靶向组合治疗癌症

    公开(公告)号：US20120294867A1

    公开(公告)日：2012-11-22

    申请号：US13471500

    申请日：2012-05-15

    申请人： Louis DENIS ,  Robert Michael LORENCE ,  Mehdi SHAHIDI ,  Flavio SOLCA

    发明人： Louis DENIS ,  Robert Michael LORENCE ,  Mehdi SHAHIDI ,  Flavio SOLCA

    IPC分类号： A61K39/395 ,  A61P35/04 ,  A61P35/00

    CPC分类号： A61K39/39558 ,  A61K31/517 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/2863 ,  A61K2300/00

    摘要： The present invention relates to a method of treating patients suffering from cancers driven by deregulated Human Epidermal Growth Factor Receptor (HER/Human EGFR), wherein an irreversible tyrosine kinase inhibitor (TKI) is administered according to a continuous regimen based on an average daily dose in the range of 10 to 50 mg and the mAB is co-administered according to a dosing regimen ranging from an average weekly iv dose of 50 to 500 mg/m2 repeated thrice, twice or once a week, once in two weeks, once in three weeks or at least monthly to a patient in need of such treatment.

    摘要翻译： 本发明涉及一种治疗患有由失调的人表皮生长因子受体（HER / Human EGFR）驱动的癌症的患者的方法，其中根据平均每日剂量的连续方案施用不可逆的酪氨酸激酶抑制剂（TKI） 在10至50mg的范围内，mAB根据给药方案共同施用，范围从50-500mg / m2的平均每周iv剂量重复三次，每周两次或一次，两周一次，一次在两周内 三周或至少每月一次需要这种治疗的患者。

    METHOD FOR EGFR DIRECTED COMBINATION TREATMENT OF CANCER
    5.
    发明申请
    METHOD FOR EGFR DIRECTED COMBINATION TREATMENT OF CANCER 审中-公开
    方法用于EGFR靶向组合治疗癌症

    公开(公告)号：US20140341926A1

    公开(公告)日：2014-11-20

    申请号：US14450342

    申请日：2014-08-04

    申请人： Louis DENIS ,  Robert Michael LORENCE ,  Mehdi SHAHIDI ,  Flavio SOLCA

    发明人： Louis DENIS ,  Robert Michael LORENCE ,  Mehdi SHAHIDI ,  Flavio SOLCA

    IPC分类号： A61K39/395 ,  A61K45/06

    CPC分类号： A61K39/39558 ,  A61K31/517 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/2863 ,  A61K2300/00

    摘要： The present invention relates to a method of treating patients suffering from cancers driven by deregulated Human Epidermal Growth Factor Receptor (HER/Human EGFR), wherein an irreversible tyrosine kinase inhibitor (TKI) is administered according to a continuous regimen based on an average daily dose in the range of 10 to 50 mg and the mAB is co-administered according to a dosing regimen ranging from an average weekly iv dose of 50 to 500 mg/m2 repeated thrice, twice or once a week, once in two weeks, once in three weeks or at least monthly to a patient in need of such treatment.

    摘要翻译： 本发明涉及一种治疗患有由失调的人表皮生长因子受体（HER / Human EGFR）驱动的癌症的患者的方法，其中根据平均每日剂量的连续方案施用不可逆的酪氨酸激酶抑制剂（TKI） 在10至50mg的范围内，mAB根据给药方案共同施用，范围从50-500mg / m2的平均每周iv剂量重复三次，每周两次或一次，两周一次，一次在两周内 三周或至少每月一次需要这种治疗的患者。

    Method for treating abnormal cell growth
    6.
    发明申请
    Method for treating abnormal cell growth 审中-公开
    治疗异常细胞生长的方法

    公开(公告)号：US20050272755A1

    公开(公告)日：2005-12-08

    申请号：US11145097

    申请日：2005-06-03

    申请人： Louis Denis ,  Linda Compton

    发明人： Louis Denis ,  Linda Compton

    IPC分类号： A61K31/4745 ,  A61K31/7068 ,  A61K45/06

    CPC分类号： A61K31/7068 ,  A61K31/4745 ,  A61K45/06 ,  A61K2300/00

    摘要： The present Invention relates to a method of treating abnormal cell growth in a subject, comprising administering to said subject having abnormal cell growth: (a) a compound selected from the group consisting of a camptothecin, a camptothecin derivative, or a pharmaceutically acceptable salt, solvate or prodrug of said compounds; (b) a pyrimidine derivative or a pharmaceutically acceptable salt, solvate or prodrug of said pyrimidine derivative; and (c) an anti-tumor agent selected from the group consisting of antiproliferative agents, kinase inhibitors, angiogenesis inhibitors, growth factor inhibitors, cox-I inhibitors, cox-II inhibitors, mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, radiation, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, antibodies, cytotoxics, anti-hormones, anti-androgens and combinations thereof.

    摘要翻译： 本发明涉及一种治疗受试者异常细胞生长的方法，包括对所述具有异常细胞生长的受试者施用：（a）选自喜树碱，喜树碱衍生物或其药学上可接受的盐的化合物， 所述化合物的溶剂合物或前药; （b）所述嘧啶衍生物的嘧啶衍生物或药学上可接受的盐，溶剂合物或前药; 选自抗增生剂，激酶抑制剂，血管生成抑制剂，生长因子抑制剂，cox-1抑制剂，cox-II抑制剂，有丝分裂抑制剂，烷化剂，抗代谢物，插入抗生素的抗肿瘤剂 ，生长因子抑制剂，辐射，细胞周期抑制剂，酶，拓扑异构酶抑制剂，生物反应调节剂，抗体，细胞毒素，抗激素，抗雄激素及其组合。